Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17655795 | 1.00 | SLC6A3 (0.79) | SLC6A3SLC6A2SLC6A4DRD3 | |
| SCHEMBL4931136 | 0.99 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4DRD3 | |
| Hydrochloric Acid SCHEMBL29398571 | 0.97 | SLC6A3 (0.79) | SLC6A3SLC6A2SLC6A4DRD3 | |
| SCHEMBL21271156 | 0.94 | SLC6A3 (0.83) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27098434 | 0.93 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27098438 | 0.93 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4936204 | 0.88 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30624700 | 0.87 | SLC6A3 (0.97) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17661659 | 0.86 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27098435 | 0.83 | SLC6A3 (0.69) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222761821-U | Transformer insulating oil seepage overhauls device | 广西送变电建设有限责任公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118846122-B | Nanoparticle for targeted regulation of meningeal lymphatic system as well as preparation method and application thereof | 海南大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119199463-B | IGBT internal defect positioning method and device based on current rising transient process | 华北电力科学研究院有限责任公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119199463-A | IGBT internal defect positioning method and device based on current rising transient process | 华北电力科学研究院有限责任公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118846122-A | Nanoparticle for targeted regulation of meningeal lymphatic system as well as preparation method and application thereof | 海南大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118468764-A | Temperature criterion setting method for identifying IGBT aging state | 北京交通大学 | 2024-08-09 | — | — | CN | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| CN-116794478-A | Thyristor junction temperature extraction method based on thyristor switching delay time | 国网安徽省电力有限公司电力科学研究院 | 2023-09-22 | — | — | CN | claimed |
| CN-116736063-A | IGBT state evaluation method based on weighted LSTM | 安徽大学 | 2023-09-12 | — | — | CN | claimed |
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) | 2008-09-25 | — | — | US | claimed |
| EP-1670755-A4 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | HARVARD COLLEGE (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1670755-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | President And Fellows of Harvard College (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005034878-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-04-21 | — | — | WO | claimed |
| US-20260090989-A1 | LIPID NANOPARTICLE mRNA VACCINES | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-12576040-B2 | Ionizable lipids and methods of manufacture and use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-03-17 | — | — | US | disclosed |
| US-12571799-B2 | Biomarkers for determining the efficacy of immune checkpoint inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1670755-A4 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | HARVARD COLLEGE (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1670755-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | President And Fellows of Harvard College (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034878-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885SLC6A4 2/4885 |
| US-12576040-B2 | Ionizable lipids and methods of manufacture and use thereof | NPC1L1, NSUN3, CETP | SLC6A3 3267/4885SLC6A2 3726/4885SLC6A4 3672/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | SLC6A3 2300/4885SLC6A2 941/4885SLC6A4 1826/4885 |
| US-20260090989-A1 | LIPID NANOPARTICLE mRNA VACCINES | RNMT, NSUN3, SARNP | SLC6A3 2107/4885SLC6A2 1879/4885SLC6A4 2692/4885 |
| US-12571799-B2 | Biomarkers for determining the efficacy of immune checkpoint inhibitors | CD274, PDCD1, PDCD1LG2 | SLC6A3 3870/4885SLC6A2 3475/4885SLC6A4 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.